Status:
UNKNOWN
Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion
Lead Sponsor:
Royal Centre for Defence Medicine
Collaborating Sponsors:
Leeds Beckett University
Liverpool John Moores University
Conditions:
SARS-CoV Infection
Vitamin D Deficiency
Eligibility:
All Genders
18-30 years
Phase:
NA
Brief Summary
This study is intended to address the association between vitamin D status and seroconversion to SARS-CoV-2 in healthy young adults. The primary aim of the study is to determine the rates of 'silent'...
Detailed Description
The primary aim of the study is to determine the rates of 'silent' seroconversion rates, consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population with a wide spread...
Eligibility Criteria
Inclusion
- Able to access the study sites at Leeds Beckett University's Headingley or City campuses, UK OR recruit at Infantry Training Centre, Catterick Garrison, UK
- In possession of an internet-enabled smart phone capable of receiving and responding to smartphone alerts.
Exclusion
- Previously diagnosed with COVID-19 either by RT-PCR or serologically (either prior to the study or at initial baseline testing).
- Use of over-the-counter or prescribed vitamin D supplements currently or in the past month
- Condition conferring 'very high risk' or 'high risk' of severe COVID-19
- have had an organ transplant
- are having chemotherapy or antibody treatment for cancer, including immunotherapy
- are having an intense course of radiotherapy (radical radiotherapy) for lung cancer
- are having targeted cancer treatments that can affect the immune system (such as protein kinase inhibitors or PARP inhibitors)
- have blood or bone marrow cancer (such as leukaemia, lymphoma or myeloma)
- have had a bone marrow or stem cell transplant in the past 6 months, or are still taking immunosuppressant medicine
- are pregnant or intent on becoming pregnant during the anticipated study period
- have a learning disability
- have a lung condition (such as cystic fibrosis, asthma, COPD, emphysema or bronchitis)
- have heart disease (such as heart failure)
- have high blood pressure (hypertension)
- have diabetes
- have chronic kidney disease
- have liver disease (such as hepatitis)
- have a condition affecting the brain or nerves (such as Parkinson's disease, motor neurone disease, multiple sclerosis, or cerebral palsy)
- have a problem with the spleen or have had the spleen removed
- have a condition with high risk of getting infections (such as SCID, sickle cell, HIV, lupus or scleroderma)
- are taking medicine that can affect the immune system (such as steroids)
- are very obese (a BMI of 40 or above)
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 28 2021
Estimated Enrollment :
900 Patients enrolled
Trial Details
Trial ID
NCT04476680
Start Date
September 1 2020
End Date
April 28 2021
Last Update
March 23 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Headingley and City campuses, Leeds Beckett University
Leeds, Yorkshire, United Kingdom, LS6 3QQ
2
Infantry Training Centre Catterick
Catterick Garrison, United Kingdom, DL9 4HH